Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review
  • Published:

The role of hematopoietic SCT in adult Burkitt lymphoma

Bone Marrow Transplantation volume 48, pages 617–629 (2013)Cite this article

Subjects

Abstract

Adult Burkitt lymphoma (BL) is an aggressive disease characterized by frequent extranodal presentation, bulky disease and a rapid clinical course. Although intensive chemotherapeutic regimes result in long-term disease-free survival in most patients, a significant proportion of patients will have high-risk disease that may be refractory or that will relapse. In these patients, the role of hematopoietic SCT is not well defined, especially in the era of modern chemoimmunotherapy. Upfront auto-SCT has been reported to be feasible in patients who have high-risk features at presentation, and in whom it is a clinical option. In patients with relapsed disease, auto-SCT can result in a PFS of 30–40%. Allo-SCT is an option in relapsing patients with a sibling or matched related donor who may not be eligible for, or may have previously received, an auto-SCT; the role of RIC and T-cell depletion is not well defined. Disease status at transplant is the most significant predictor of outcome in patients undergoing SCT. Here we review the available evidence pertaining to SCT in patients with BL, including in those who are HIV positive (HIV+) and those with B-cell lymphoma unclassified (BCLU). Prospective studies in the era of modern intensive chemoimmunotherapeutic regimes are required to delineate the precise role of transplantation for BL. Developments in molecular diagnostics, incorporation of FDG-PET and minimal residual disease monitoring along with new therapies may further assist in refining treatment algorithms.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Blum KA, Lozanski G, Byrd JC . Adult Burkitt leukemia and lymphoma. Blood 2004; 104: 3009–3020.

    Article  CAS  PubMed  Google Scholar 

  2. Leonici LRM, Stein H, Harris N, Jaffe E, Kluin P . Burkitt Lymphoma. In: Swerdelow SCE, Harris N, Jaffe E, Pileri S, Stein H, Thiele J, Vardiman J, (eds). WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues 4th edn. IARC: Lyon, 2008 pp 262–264.

    Google Scholar 

  3. Hecht JL, Aster JC . Molecular biology of Burkitt’s lymphoma. J Clin Oncol 2000; 18: 3707–3721.

    Article  CAS  PubMed  Google Scholar 

  4. Macpherson N, Lesack D, Klasa R, Horsman D, Connors JM, Barnett M et al. Small noncleaved, non-Burkitt’s (Burkit-Like) lymphoma: cytogenetics predict outcome and reflect clinical presentation. J Clin Oncol 1999; 17: 1558–1567.

    Article  CAS  PubMed  Google Scholar 

  5. Aukema SM, Siebert R, Schuuring E, van Imhoff GW, Kluin-Nelemans HC, Boerma E-J et al. Double-hit B-cell lymphomas. Blood 2011; 117: 2319–2331.

    Article  CAS  PubMed  Google Scholar 

  6. Hummel M, Bentink S, Berger H, Klapper W, Wessendorf S, Barth TF et al. A biologic definition of Burkitt’s lymphoma from transcriptional and genomic profiling. N Engl J Med 2006; 354: 2419–2430.

    Article  CAS  PubMed  Google Scholar 

  7. Dave SS, Fu K, Wright GW, Lam LT, Kluin P, Boerma EJ et al. Molecular diagnosis of Burkitt’s lymphoma. N Engl J Med 2006; 354: 2431–2442.

    Article  CAS  PubMed  Google Scholar 

  8. Naresh KN, Ibrahim HA, Lazzi S, Rince P, Onorati M, Ambrosio MR et al. Diagnosis of Burkitt lymphoma using an algorithmic approach - applicable in both resource-poor and resource-rich countries. Br J Haematol 2011; 154: 770–776.

    Article  PubMed  Google Scholar 

  9. Magrath I, Adde M, Shad A, Venzon D, Seibel N, Gootenberg J et al. Adults and children with small non-cleaved-cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen. J Clin Oncol 1996; 14: 925–934.

    Article  CAS  PubMed  Google Scholar 

  10. Mead GM, Sydes MR, Walewski J, Grigg A, Hatton CS, Pescosta N et al. An international evaluation of CODOX-M and CODOX-M alternating with IVAC in adult Burkitt’s lymphoma: results of United Kingdom Lymphoma Group LY06 study. Ann Oncol 2002; 13: 1264–1274.

    Article  CAS  PubMed  Google Scholar 

  11. Thomas DA, Cortes J, O’Brien S, Pierce S, Faderl S, Albitar M et al. Hyper-CVAD program in Burkitt’s-type adult acute lymphoblastic leukemia. J Clin Oncol 1999; 17: 2461–2470.

    Article  CAS  PubMed  Google Scholar 

  12. Thomas DA, Faderl S, O’Brien S, Bueso-Ramos C, Cortes J, Garcia-Manero G et al. Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. Cancer 2006; 106: 1569–1580.

    Article  CAS  PubMed  Google Scholar 

  13. Soussain C, Patte C, Ostronoff M, Delmer A, Rigal-Huguet F, Cambier N et al. Small noncleaved cell lymphoma and leukemia in adults. A retrospective study of 65 adults treated with the LMB pediatric protocols. Blood 1995; 85: 664–674.

    Article  CAS  PubMed  Google Scholar 

  14. Divine M, Casassus P, Koscielny S, Bosq J, Sebban C, Le Maignan C et al. Burkitt lymphoma in adults: a prospective study of 72 patients treated with an adapted pediatric LMB protocol. Ann Oncol 2005; 16: 1928–1935.

    Article  CAS  PubMed  Google Scholar 

  15. McMaster ML, Greer JP, Greco FA, Johnson DH, Wolff SN, Hainsworth JD . Effective treatment of small-noncleaved-cell lymphoma with high-intensity, brief-duration chemotherapy. J Clin Oncol 1991; 9: 941–946.

    Article  CAS  PubMed  Google Scholar 

  16. Barnes JA, LaCasce AS, Feng Y, Toomey CE, Neuberg D, Michaelson JS et al. Evaluation of the addition of rituximab to CODOX-M/IVAC for Burkitt’s lymphoma: a retrospective analysis. Ann Oncol 2011; 22: 1859–1864.

    Article  CAS  PubMed  Google Scholar 

  17. Mohamedbhai SG, Sibson K, Marafioti T, Kayani I, Lowry L, Goldstone AH et al. Rituximab in combination with CODOX-M/IVAC: a retrospective analysis of 23 cases of non-HIV related B-cell non-Hodgkin lymphoma with proliferation index >95%. Br J Haematol 2011; 152: 175–181.

    Article  CAS  PubMed  Google Scholar 

  18. Cortes J, Thomas D, Rios A, Koller C, O’Brien S, Jeha S et al. Hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone and highly active antiretroviral therapy for patients with acquired immunodeficiency syndrome-related Burkitt lymphoma/leukemia. Cancer 2002; 94: 1492–1499.

    Article  CAS  PubMed  Google Scholar 

  19. Mead GM, Barrans SL, Qian W, Walewski J, Radford JA, Wolf M et al. A prospective clinicopathologic study of dose-modified CODOX-M/IVAC in patients with sporadic Burkitt lymphoma defined using cytogenetic and immunophenotypic criteria (MRC/NCRI LY10 trial). Blood 2008; 112: 2248–2260.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Shipp M, Harrington D, Andersen J, Armitage J, Bonadonna G, Brittinger G et al. A predictive model for aggressive non-Hodgkin’s lymphoma. The international non-Hodgkin’s lymphoma prognostic factors project. N Engl J Med 1993; 329: 987–994.

    Article  Google Scholar 

  21. Kelly JL, Toothaker SR, Ciminello L, Hoelzer D, Holte H, LaCasce AS et al. Outcomes of patients with Burkitt lymphoma older than age 40 treated with intensive chemotherapeutic regimens. Clin Lymphoma Myeloma 2009; 9: 307–310.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Lee EJ, Petroni GR, Schiffer CA, Freter CE, Johnson JL, Barcos M et al. Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251. J Clin Oncol 2001; 19: 4014–4022.

    Article  CAS  PubMed  Google Scholar 

  23. Haioun C, Lepage E, Gisselbrecht C, Coiffier B, Bosly A, Tilly H et al. Comparison of autologous bone marrow transplantation with sequential chemotherapy for intermediate-grade and high-grade non-Hodgkin’s lymphoma in first complete remission: a study of 464 patients. Groupe d’Etude des Lymphomes de l’Adulte. J Clin Oncol 1994; 12: 2543–2551.

    Article  CAS  PubMed  Google Scholar 

  24. Wasterlid T, Jonsson B, Hagberg H, Jerkeman M . Population based study of prognostic factors and treatment in adult Burkitt lymphoma: a Swedish Lymphoma Registry study. Leuk Lymphoma 2011; 52: 2090–2096.

    Article  PubMed  CAS  Google Scholar 

  25. Fernandez HF, Escalon MP, Pereira D, Lazarus HM . Autotransplant conditioning regimens for aggressive lymphoma: are we on the right road? Bone Marrow Transplant 2007; 40: 505–513.

    Article  CAS  PubMed  Google Scholar 

  26. Nademanee A, Molina A, O’Donnell MR, Dagis A, Snyder DS, Parker P et al. Results of high-dose therapy and autologous bone marrow/stem cell transplantation during remission in poor-risk intermediate- and high-grade lymphoma: international index high and high-intermediate risk group. Blood 1997; 90: 3844–3852.

    Article  CAS  PubMed  Google Scholar 

  27. Haioun C, Lepage E, Gisselbrecht C, Salles G, Coiffier B, Brice P et al. Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin’s lymphoma: final analysis of the prospective LNH87-2 protocol—a groupe d’Etude des lymphomes de l’Adulte study. J Clin Oncol 2000; 18: 3025–3030.

    Article  CAS  PubMed  Google Scholar 

  28. Gisselbrecht C, Lepage E, Molina T, Quesnel B, Fillet G, Lederlin P et al. Shortened first-line high-dose chemotherapy for patients with poor-prognosis aggressive lymphoma. J Clin Oncol 2002; 20: 2472–2479.

    Article  CAS  PubMed  Google Scholar 

  29. Kaiser U, Uebelacker I, Abel U, Birkmann J, Trumper L, Schmalenberg H et al. Randomized study to evaluate the use of high-dose therapy as part of primary treatment for ‘aggressive’ lymphoma. J Clin Oncol 2002; 20: 4413–4419.

    Article  CAS  PubMed  Google Scholar 

  30. Greb A, Bohlius J, Schiefer D, Schwarzer G, Schulz H, Engert A . High-dose chemotherapy with autologous stem cell transplantation in the first line treatment of aggressive Non-Hodgkin Lymphoma (NHL) in adults. Cochrane Database Syst Rev 2008; CD004024 (DOI:10.1002/14651858.CD004024.pub2).

  31. Jost LM, Jacky E, Dommann-Scherrer C, Honegger HP, Maurer R, Sauter C et al. Short-term weekly chemotherapy followed by high-dose therapy with autologous bone marrow transplantation for lymphoblastic and Burkitt’s lymphomas in adult patients. Ann Oncol 1995; 6: 445–451.

    Article  CAS  PubMed  Google Scholar 

  32. Song KW, Barnett MJ, Gascoyne RD, Horsman DE, Forrest DL, Hogge DE et al. Haematopoietic stem cell transplantation as primary therapy of sporadic adult Burkitt lymphoma. Br J Haematol 2006; 133: 634–637.

    Article  PubMed  Google Scholar 

  33. Schmitz N, Kloess M, Reiser M, Berdel WE, Metzner B, Dorken B et al. Four versus six courses of a dose-escalated cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen plus etoposide (megaCHOEP) and autologous stem cell transplantation: early dose intensity is crucial in treating younger patients with poor prognosis aggressive lymphoma. Cancer 2006; 106: 136–145.

    Article  CAS  PubMed  Google Scholar 

  34. van Imhoff GW, van der Holt B, MacKenzie MA, Ossenkoppele GJ, Wijermans PW, Kramer MH et al. Short intensive sequential therapy followed by autologous stem cell transplantation in adult Burkitt, Burkitt-like and lymphoblastic lymphoma. Leukemia 2005; 19: 945–952.

    Article  CAS  PubMed  Google Scholar 

  35. Sweetenham JW, Pearce R, Taghipour G, Blaise D, Gisselbrecht C, Goldstone AH . Adult Burkitt’s and Burkitt-like non-Hodgkin’s lymphoma—outcome for patients treated with high-dose therapy and autologous stem-cell transplantation in first remission or at relapse: results from the european group for blood and marrow transplantation. J Clin Oncol 1996; 14: 2465–2472.

    Article  CAS  PubMed  Google Scholar 

  36. Gajewski JL, Carreras J, Lazarus HM, Laport GG, Montoto S, Maloney DG et al. The role of hematopoietic cell transplantation (SCT) for burkitt lymphoma: a report from the center for international blood and marrow transplant research (CIBMTR). Blood 2010; 116: 2390a (abstract).

    Article  Google Scholar 

  37. Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007; 25: 579–586.

    Article  PubMed  Google Scholar 

  38. Karantanis D, Durski JM, Lowe VJ, Nathan MA, Mullan BP, Georgiou E et al. 18F-FDG PET and PET/CT in Burkitt’s lymphoma. Eur J Radiol 2010; 75: e68–e73.

    Article  PubMed  Google Scholar 

  39. Ljungman P, Bregni M, Brune M, Cornelissen J, de Witte T, Dini G et al. Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe 2009. Bone Marrow Transplant 2010; 45: 219–234.

    Article  CAS  PubMed  Google Scholar 

  40. Philip T, Guglielmi C, Hagenbeek A, Somers R, Van der Lelie H, Bron D et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin’s lymphoma. N Engl J Med 1995; 333: 1540–1545.

    Article  CAS  PubMed  Google Scholar 

  41. Appelbaum FR, Deisseroth AB, Graw RG, Herzig GP, Levine AS, Magrath IT et al. Prolonged complete remission following high dose chemotherapy of Burkitt’s lymphoma in relapse. Cancer 1978; 41: 1059–1063.

    Article  CAS  PubMed  Google Scholar 

  42. Nademanee A, Molina A, Dagis A, Snyder DS, O’Donnell MR, Parker P et al. Autologous stem-cell transplantation for poor-risk and relapsed intermediate- and high-grade non-Hodgkin’s lymphoma. Clin Lymphoma 2000; 1: 46–54.

    Article  CAS  PubMed  Google Scholar 

  43. Ladenstein R, Pearce R, Hartmann O, Patte C, Goldstone T, Philip T . High-dose chemotherapy with autologous bone marrow rescue in children with poor-risk Burkitt’s lymphoma: a report from the European Lymphoma Bone Marrow Transplantation Registry. Blood 1997; 90: 2921–2930.

    Article  CAS  PubMed  Google Scholar 

  44. Chakraverty R, Mackinnon S . Allogeneic transplantation for lymphoma. J Clin Oncol 2011; 29: 1855–1863.

    Article  PubMed  Google Scholar 

  45. Warlick ED, Tomblyn M, Cao Q, Defor T, Blazar BR, Macmillan M et al. Reduced-intensity conditioning followed by related allografts in hematologic malignancies: long-term outcomes most successful in indolent and aggressive non-Hodgkin lymphomas. Biol Blood Marrow Transplant 2011; 17: 1025–1032.

    Article  PubMed  Google Scholar 

  46. Troussard X, Leblond V, Kuentz M, Milpied N, Jouet JP, Cordonnier C et al. Allogeneic bone marrow transplantation in adults with Burkitt’s lymphoma or acute lymphoblastic leukemia in first complete remission. J Clin Oncol 1990; 8: 809–812.

    Article  CAS  PubMed  Google Scholar 

  47. Hamadani M, Benson DM, Hofmeister CC, Elder P, Blum W, Porcu P et al. Allogeneic stem cell transplantation for patients with relapsed chemorefractory aggressive non-hodgkin lymphomas. Biol Blood Marrow Transplant 2009; 15: 547–553.

    Article  PubMed  PubMed Central  Google Scholar 

  48. Peniket AJ, Ruiz de Elvira MC, Taghipour G, Cordonnier C, Gluckman E, de Witte T et al. An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation. Bone Marrow Transplant 2003; 31: 667–678.

    Article  CAS  PubMed  Google Scholar 

  49. van Besien K, Carreras J, Bierman PJ, Logan BR, Molina A, King R et al. Unrelated donor hematopoietic cell transplantation for non-hodgkin lymphoma: long-term outcomes. Biol Blood Marrow Transplant 2009; 15: 554–563.

    Article  PubMed  PubMed Central  Google Scholar 

  50. Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG et al. Hematopoietic cell transplantation (SCT)-specific comorbidity index: a new tool for risk assessment before allogeneic SCT. Blood 2005; 106: 2912–2919.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Maloney D . Allogeneic transplantation following nonmyeloablative conditioning for aggressive lymphoma. Bone Marrow Transplant 2008; 42 (Suppl 1): S35–S36.

    Article  PubMed  Google Scholar 

  52. Armand P, Kim HT, Ho VT, Cutler CS, Koreth J, Antin JH et al. Allogeneic transplantation with reduced-intensity conditioning for hodgkin and non-hodgkin lymphoma: importance of histology for outcome. Biol Blood Marrow Transplant 2008; 14: 418–425.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  53. Branson K, Chopra R, Kottaridis PD, McQuaker G, Parker A, Schey S et al. Role of nonmyeloablative allogeneic stem-cell transplantation after failure of autologous transplantation in patients with lymphoproliferative malignancies. J Clin Oncol 2002; 20: 4022–4031.

    Article  PubMed  Google Scholar 

  54. Robinson SP, Goldstone AH, Mackinnon S, Carella A, Russell N, de Elvira CR et al. Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation. Blood 2002; 100: 4310–4316.

    Article  CAS  PubMed  Google Scholar 

  55. Morris E, Thomson K, Craddock C, Mahendra P, Milligan D, Cook G et al. Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma. Blood 2004; 104: 3865–3871.

    Article  CAS  PubMed  Google Scholar 

  56. Schimmer AD, Jamal S, Messner H, Keating A, Meharchand J, Huebsch L et al. Allogeneic or autologous bone marrow transplantation (BMT) for non-Hodgkin’s lymphoma (NHL): results of a provincial strategy. Ontario BMT Network, Canada. Bone Marrow Transplant 2000; 26: 859–864.

    Article  CAS  PubMed  Google Scholar 

  57. Kusumi E, Kami M, Kanda Y, Murashige N, Kishi Y, Suzuki R et al. Reduced-intensity hematopoietic stem-cell transplantation for malignant lymphoma: a retrospective survey of 112 adult patients in Japan. Bone Marrow Transplant 2005; 36: 205–213.

    Article  CAS  PubMed  Google Scholar 

  58. Le Gouill S, Talmant P, Touzeau C, Moreau A, Garand R, Juge-Morineau N et al. The clinical presentation and prognosis of diffuse large B-cell lymphoma with t(14;18) and 8q24/c-MYC rearrangement. Haematologica 2007; 92: 1335–1342.

    Article  CAS  PubMed  Google Scholar 

  59. Romagnoli M, Desplanques G, Maiga S, Legouill S, Dreano M, Bataille R et al. Canonical nuclear factor kappaB pathway inhibition blocks myeloma cell growth and induces apoptosis in strong synergy with TRAIL. Clin Cancer Res 2007; 13: 6010–6018.

    Article  CAS  PubMed  Google Scholar 

  60. Grigg AP, Seymour JF . Graft versus Burkitt’s lymphoma effect after allogeneic marrow transplantation. Leuk Lymphoma 2002; 43: 889–892.

    Article  CAS  PubMed  Google Scholar 

  61. Ungkanont A, Mongkonsritrakoon W, Jootar S, Srichaikul T . Allogeneic stem cell transplantation in a patient with refractory Burkitt’s lymphoma using non-myeloablative conditioning regimen. Bone Marrow Transplant 2000; 26: 1351–1354.

    Article  CAS  PubMed  Google Scholar 

  62. Tomita N, Tokunaka M, Nakamura N, Takeuchi K, Koike J, Motomura S et al. Clinicopathological features of lymphoma/leukemia patients carrying both BCL2 and MYC translocations. Haematologica 2009; 94: 935–943.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  63. Tomita N . BCL2 and MYC dual-hit lymphoma/leukemia. J Clin Exp Hematop 2011; 51: 7–12.

    Article  PubMed  Google Scholar 

  64. Johnson NA, Savage KJ, Ludkovski O, Ben-Neriah S, Woods R, Steidl C et al. Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival. Blood 2009; 114: 2273–2279.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  65. Dann EJ, Daugherty CK, Larson RA . Allogeneic bone marrow transplantation for relapsed and refractory Hodgkin’s disease and non-Hodgkin’s lymphoma. Bone Marrow Transplant 1997; 20: 369–374.

    Article  CAS  PubMed  Google Scholar 

  66. Mbulaiteye SM, Anderson WF, Bhatia K, Rosenberg PS, Linet MS, Devesa SS . Trimodal age-specific incidence patterns for Burkitt lymphoma in the United States, 1973–2005. Int J Cancer 2010; 126: 1732–1739.

    CAS  PubMed  PubMed Central  Google Scholar 

  67. Oriol A, Ribera J-M, Bergua J, Giménez Mesa E, Grande C, Esteve J et al. High-dose chemotherapy and immunotherapy in adult Burkitt lymphoma. Cancer 2008; 113: 117–125.

    Article  CAS  PubMed  Google Scholar 

  68. Rizzieri DA, Johnson JL, Niedzwiecki D, Lee EJ, Vardiman JW, Powell BL et al. Intensive chemotherapy with and without cranial radiation for Burkitt leukemia and lymphoma: final results of Cancer and Leukemia Group B Study 9251. Cancer 2004; 100: 1438–1448.

    Article  CAS  PubMed  Google Scholar 

  69. Balsalobre P, Diez-Martin JL, Re A, Michieli M, Ribera JM, Canals C et al. Autologous stem-cell transplantation in patients with HIV-related lymphoma. J Clin Oncol 2009; 27: 2192–2198.

    Article  PubMed  Google Scholar 

  70. Diez-Martin JL, Balsalobre P, Re A, Michieli M, Ribera JM, Canals C et al. Comparable survival between HIV+ and HIV− non-Hodgkin and Hodgkin lymphoma patients undergoing autologous peripheral blood stem cell transplantation. Blood 2009; 113: 6011–6014.

    Article  CAS  PubMed  Google Scholar 

  71. Krishnan A, Molina A, Zaia J, Smith D, Vasquez D, Kogut N et al. Durable remissions with autologous stem cell transplantation for high-risk HIV-associated lymphomas. Blood 2005; 105: 874–878.

    Article  CAS  PubMed  Google Scholar 

  72. Gupta V, Tomblyn M, Pedersen TL, Atkins HL, Battiwalla M, Gress RE et al. Allogeneic hematopoietic cell transplantation in human immunodeficiency virus-positive patients with hematologic disorders: a report from the center for international blood and marrow transplant research. Biol Blood Marrow Transplant 2009; 15: 864–871.

    Article  PubMed  PubMed Central  Google Scholar 

  73. Tholouli E, Watt S, Lucas GS, Burthem J, Yin JA, Cavet J et al. Stage IV adult sporadic Burkitt lymphoma/leukemia with complex bone marrow cytogenetics is associated with a very poor outcome. Blood 2009; 114: 485–486 ; author reply 486–487.

    Article  CAS  PubMed  Google Scholar 

  74. Agsalda M, Kusao I, Troelstrup D, Shiramizu B . Screening for residual disease in pediatric burkitt lymphoma using consensus primer pools. Adv Hematol 2009; 2009: 412163.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  75. Shiramizu B, Goldman S, Kusao I, Agsalda M, Lynch J, Smith L et al. Minimal disease assessment in the treatment of children and adolescents with intermediate-risk (Stage III/IV) B-cell non-Hodgkin lymphoma: a children’s oncology group report. Br J Haematol 2011; 153: 758–763.

    Article  PubMed  PubMed Central  Google Scholar 

  76. Mussolin L, Pillon M, d’Amore ESG, Conter V, Piglione M, Lo Nigro L et al. Minimal disseminated disease in high-risk Burkitt’s lymphoma identifies patients with different prognosis. J Clin Oncol 2011; 29: 1779–1784.

    Article  PubMed  Google Scholar 

  77. Patte C, Auperin A, Gerrard M, Michon J, Pinkerton R, Sposto R et al. Results of the randomized international FAB/LMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescents: it is possible to reduce treatment for the early responding patients. Blood 2007; 109: 2773–2780.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  78. Zelenetz AD, Abramson JS, Advani RH, Andreadis CB, Byrd JC, Czuczman MS et al. NCCN Clinical Practice Guidelines in Oncology: non-Hodgkin’s lymphomas. J Natl Compr Canc Netw 2010; 8: 288–334.

    Article  PubMed  Google Scholar 

  79. Majhail NS, Bajorunaite R, Lazarus HM, Wang Z, Klein JP, Zhang MJ et al. Long-term survival and late relapse in 2-year survivors of autologous haematopoietic cell transplantation for Hodgkin and non-Hodgkin lymphoma. Br J Haematol 2009; 147: 129–139.

    Article  PubMed  PubMed Central  Google Scholar 

  80. Gada P, Defor T, Weisdorf DJ, Miller JS, Orchard PJ, MacMillan ML et al. Prolonged remissions with autologous and allogeneic stem cell transplantation for Burkitt’s lymphoma: long term follow-up at a single institution. Blood 2005; 106: 1133a (abstract).

    Article  Google Scholar 

  81. Kwon S, Steinberg A, Bresee C, Franco M, Lopez AM, Lim S et al. Stem cell transplantation for relapsed and refractory burkitt lymphoma. Blood 2010; 116: 4589a (abstract).

    Article  Google Scholar 

  82. Snuderl M, Kolman OK, Chen YB, Hsu JJ, Ackerman AM, Dal Cin P et al. B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma. Am J Surg Pathol 2010; 34: 327–340.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

We thank Professor K Naresh, Dr Ed Kanfer and the reviewers for their insightful comments, and are ever grateful for the assistance provided by the late Jian Jian Luan in collating and analyzing the EBMT data.

Author information

Authors and Affiliations

  1. Department of Hematology, Hammersmith Hospital, Imperial College Healthcare NHS Trust, London, UK

    S O Ahmed

  2. Department of Hematology, Addenbrooke’s Hospital, Cambridge, UK

    A Sureda

  3. Adult Hematopoietic Stem Cell Transplantation Program, Section of Adult Hematology/SCT, Oncology Center, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia

    M Aljurf

Authors
  1. S O Ahmed
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A Sureda
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M Aljurf
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M Aljurf.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ahmed, S., Sureda, A. & Aljurf, M. The role of hematopoietic SCT in adult Burkitt lymphoma. Bone Marrow Transplant 48, 617–629 (2013). https://doi.org/10.1038/bmt.2012.129

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2012.129

Keywords

This article is cited by

Search

Advanced search

Quick links